Summary
This study is open to adults aged 18 and older or above legal age who have a specific
type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker
called DLL3.
The purpose of this study is to test a medicine called BI 764532 in addition to
chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest
dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of
Part B is to find out how well people can tolerate BI 764532 in combination with
different chemotherapies. Researchers also want to find out whether BI 764532 in
combination with chemotherapy helps people with NEC.
Participants get different doses of BI 764532 as an infusion into a vein. In addition,
they get platinum-based chemotherapy as infusions into a vein. Participants can continue
treatment up to 3 years if they benefit from treatment and can tolerate it.
Participants visit their doctors regularly. During these visits, the doctors collect
information about participants' health and take note of any unwanted effects. Doctors
also regularly check the size of the tumour.